Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 41 results
Filters: First Letter Of Title is H  [Clear All Filters]
Found 41 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

H

Abu-Raddad LJ, Barnabas RV, Janes H, et al. "Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?" AIDS. 2013;27(6):981-9.
Kemmer N, Hua L, Andersen JW, Chung RT, Butt AA, Sherman KE. "Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study." J. Viral Hepat.. 2012;19(11):792-800.
Behler CM, Vittinghoff E, Lin F, et al. "Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects." Clin. Infect. Dis.. 2007;44(10):1375-83.
Hulgan T, Tebas P, Canter JA, et al. "Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy." J. Infect. Dis.. 2008;197(6):858-66.
Kallianpur AR, Hulgan T, Canter JA, et al. "Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy." AIDS. 2006;20(11):1503-13.
Cramer YS, Rosenkranz SL, Hall SD, Szczech LA, Amorosa V, Gupta SK. "Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177." J. Acquir. Immune Defic. Syndr.. 2010;54(4):e7-9.
Sherman KE, Rouster SD, Stanford S, et al. "Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens." J. Infect. Dis.. 2010;201(5):712-9.
Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. "Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment." AIDS. 2013;27(17):2725-34.
Haas DW, Koletar SL, Laughlin L, et al. "Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir." J. Acquir. Immune Defic. Syndr.. 2009;50(3):290-3.
Cachay ER, Frost SDW, Richman DD, Smith DM, Little SJ. "Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection." J. Infect. Dis.. 2007;195(9):1270-7.
Healy B, Degruttola V. "Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses." Biostatistics. 2007;8(2):438-52.
Huang Y, Liu D, Wu H. "Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system." Biometrics. 2006;62(2):413-23.
Shiboski CH, Chen H, Secours R, et al. "High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group." PLoS ONE. 2015;10(7):e0131001.
Keane NM, Roberts SG, Almeida C-AM, et al. "High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection." Immunol. Cell Biol.. 2012;90(2):224-34.
J Chang J, Woods M, Lindsay RJ, et al. "Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication." J. Infect. Dis.. 2013;208(5):830-8.
Wilkin T, Lee JY, Lensing SY, et al. "High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine." HIV Clin Trials. 2013;14(2):75-9.
Fichtenbaum CJ, Evans SE, Aberg JA. "High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection." AIDS. 2011;25(16):2053.
Shah, iv S, Mildvan D. "HIV and aging." Curr Infect Dis Rep. 2006;8(3):241-7.
Yonkers NL, Rodriguez B, Post AB, et al. "HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells." J. Infect. Dis.. 2006;194(3):391-400.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.
Bronke C, Almeida C-AM, McKinnon E, et al. "HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes." AIDS. 2013;27(6):899-905.
Simpson DM, Kitch D, Evans SR, et al. "HIV neuropathy natural history cohort study: assessment measures and risk factors." Neurology. 2006;66(11):1679-87.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. "HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial." Ann. Intern. Med.. 2015;163(12):908-17.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
Landovitz RJ, Tran TTien T, Cohn SE, et al. "HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States." AIDS Behav. 2016.
Mollan K, Daar ES, Sax PE, et al. "HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status." J. Infect. Dis.. 2012;206(12):1920-30.
Putcharoen O, Lee SHee, Henrich TJ, et al. "HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug." J. Virol.. 2012;86(2):1119-28.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Mitsuya Y, Winters MA, W Fessel J, et al. "HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL." J. Acquir. Immune Defic. Syndr.. 2006;43(1):56-9.

Pages